Yohei Kubota
Overview
Explore the profile of Yohei Kubota including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsubara K, Hayakawa N, Kubota Y, Ohike N, Sunakawa Y, Koike J, et al.
IJU Case Rep
. 2025 Mar;
8(2):158-161.
PMID: 40034910
Introduction: Secondary bladder tumor is rare. We report a case of a bladder tumor initially thought to be a recurrence of non-muscle invasive bladder cancer that was ultimately identified as...
2.
Kubota Y, Sunakawa Y
Gan To Kagaku Ryoho
. 2024 Oct;
51(9):896-902.
PMID: 39462623
No abstract available.
3.
Takeda H, Yamamoto H, Oikawa R, Umemoto K, Arai H, Mizukami T, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2300425.
PMID: 39116356
Purpose: Panel-based comprehensive genomic profiling (CGP) is used in clinical practice worldwide; however, large real-world data (RWD) of patients with advanced small intestine cancer have not been characterized. We investigated...
4.
Yamamoto H, Arai H, Oikawa R, Umemoto K, Takeda H, Mizukami T, et al.
Target Oncol
. 2024 Apr;
19(3):459-471.
PMID: 38613733
Background: Panel-based comprehensive genomic profiling is used in clinical practice worldwide; however, large real-world datasets of patients with advanced gastric cancer are not well known. Objective: We investigated what differences...
5.
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou F, et al.
Eur J Cancer
. 2024 Feb;
201:113914.
PMID: 38359495
Background: CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic...
6.
Kubota Y, Shitara K
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231217967.
PMID: 38188462
Claudins (CLDNs) are a family of major membrane proteins that form components of tight junctions. In normal tissues, CLDNs seal the intercellular space in the epithelial sheets to regulate tissue...
7.
Kubota Y, Aoki Y, Kawazoe A, Shitara K
Cancer Manag Res
. 2022 Oct;
14:3083-3094.
PMID: 36275782
Recently, immune checkpoint inhibitor (ICI), such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies, has provided clinical benefits in various cancer types including advanced gastric...
8.
Aoki Y, Kawazoe A, Kubota Y, Chida K, Mishima S, Kotani D, et al.
Int J Clin Oncol
. 2022 Jun;
27(9):1413-1420.
PMID: 35713753
Background: Although several randomized trials (RCTs) showed survival benefits of immune checkpoint inhibitor (ICI) plus first-line chemotherapy for advanced gastric or gastroesophageal cancer (AGC), these trials could enroll patients who...
9.
Kubota Y, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y, et al.
Clin Cancer Res
. 2020 Mar;
26(14):3784-3790.
PMID: 32156744
Purpose: We evaluated the association between molecular subtypes of advanced gastric cancer (AGC) and the efficacy of standard chemotherapy or immune checkpoint inhibitors. Experimental Design: Patients with AGC who received...
10.
Kubota Y, Toh Yoon E
Case Rep Med
. 2018 Jul;
2018:6749432.
PMID: 30034475
[This corrects the article DOI: 10.1155/2018/8439791.].